CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study

BACKGROUND: The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association betwee...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Am Heart Assoc
Päätekijät: McDonough, Caitrin W, McClure, Leslie A, Mitchell, Braxton D, Gong, Yan, Horenstein, Richard B, Lewis, Joshua P, Field, Thalia S, Talbert, Robert L, Benavente, Oscar R, Johnson, Julie A, Shuldiner, Alan R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2015
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599525/
https://ncbi.nlm.nih.gov/pubmed/26019129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001652
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia